Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 14.77
- Piotroski Score 6.00
- Grade Buy
- Symbol (LGND)
- Company Ligand Pharmaceuticals Incorporated
- Price $110.93
- Changes Percentage (0.64%)
- Change $0.71
- Day Low $108.31
- Day High $111.59
- Year High $115.53
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 07/02/2010
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $135.00
- High Stock Price Target $157.00
- Low Stock Price Target $90.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $5.35
- Trailing P/E Ratio 15.21
- Forward P/E Ratio 15.21
- P/E Growth 15.21
- Net Income $52.15 M
Income Statement
Quarterly
Annual
Latest News of LGND
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable
Ligand Pharmaceuticals' stock has increased by 10% in the last quarter, yet it has fallen 38% over the past three years, not meeting market returns. Despite EPS growth, revenue decline suggests a need...
By Yahoo! Finance | 4 months ago
